| Term 
 | Definition 
 
        | Inhibits carbonic anhydrase |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | reduces reabsorption of bicarb in the proximal tubule, causing self-limited diuresis, hyperchloremic metabolic acidosis reduces body pH, reduced intraocular pressure |  | 
        |  | 
        
        | Term 
 
        | Acetazolamide - clinical applications? |  | Definition 
 
        | Glaucoma, mountain sickness, edema with alkalosis |  | 
        |  | 
        
        | Term 
 
        | Acetazolamide - kinetics, tox? |  | Definition 
 
        | oral and topical, 8-12 hr DOA, tox - metabolic acidosis, rental stones, hyperammonia in cirrhotics |  | 
        |  | 
        
        | Term 
 
        | What kind of drugs are brinzolamide and dorzolamide? What are they used for? |  | Definition 
 
        | carbonic anhydrase inhibitors, topical for glaucoma |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibits the Na/K/2Cl transporter in the thick ascending limb |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Marked increase in NaCl excretion, some K wasting, hypokalemic metabolic acidosis, increased URINE Ca and Mg |  | 
        |  | 
        
        | Term 
 
        | Furosemide - clinical applications? |  | Definition 
 
        | Pulmonary edema, peripheral edema, hypertension, acute hypercalcemia or hyperkalemia, acute renal failure, anion overdose |  | 
        |  | 
        
        | Term 
 
        | Furosemide - kinetics, tox? |  | Definition 
 
        | Oral and parenteral, 2-4hr DOA, ototoxicity, hypovolemia, K wasting, hyperuricemia, hypomagnesemia |  | 
        |  | 
        
        | Term 
 
        | What are bumetanide and torsemide? |  | Definition 
 
        | Sulfonamide loop agents like furosemide |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Not a sulfonamide but has typical loop activity and some uricosuric action |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Inhibition of the Na/Cl transporter in the distal convoluted tubule |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Modest increase in NaCl excretion, some K wasting, hypokalemic metabolic alkalosis, decreased urine Ca |  | 
        |  | 
        
        | Term 
 
        | HCTZ - clinical applications? |  | Definition 
 
        | HTN, mild heart failure, nephrolithiasis, nephrogenic diabetes insipidus |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Oral, duration 8-12 hr, hypokalemic metabolic acidosis, hyperuricemia, hyperglycemia, hyponatremia |  | 
        |  | 
        
        | Term 
 
        | Metazoline is popular for use WITH what types of drugs? |  | Definition 
 
        | loop agents, for synergistic effect |  | 
        |  | 
        
        | Term 
 
        | What is the only parenteral thiazide available? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | pharmacologist antagonist of aldosterone, weak antagonism of androgen receptors |  | 
        |  | 
        
        | Term 
 
        | Spironolactone - effects? |  | Definition 
 
        | Reduces Na retention and K wasting, poorly understood antagonism of aldosterone in heart and vessels |  | 
        |  | 
        
        | Term 
 
        | Spironolactone - clinical applications? |  | Definition 
 
        | aldosteronism from any cause, hypokalemia occurring from other diuretics, post-MI |  | 
        |  | 
        
        | Term 
 
        | Spironolactone - kinetics, tox? |  | Definition 
 
        | Slow onset and offset, 24-28 hr duration, hyperkalemia, gynecomastia, additive interaction with other K-sparing drugs |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Blocks epithelial sodium channels in collecting tubules |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Reduces Na retention and K wasting, increases lithium clearance |  | 
        |  | 
        
        | Term 
 
        | Amiloride - clinical applications? |  | Definition 
 
        | hypokalemia occurring from other diuretics, reduces lithium-induced polyuria |  | 
        |  | 
        
        | Term 
 
        | Amiloride - kinetics, tox? |  | Definition 
 
        | orally active, duration 24h, hyperkalemic metabolic acidosis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Like spironolactone, more selective for aldosterone receptor |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | mechanism like amiloride, much less potent and more toxic |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mechanism like amiloride, much less potent and more toxic |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | physical osmotic effect, contained in the vascular compartment |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | marked increase in urine flow, reduced brain volume, decreased IOP, initial hyponatremia, then hypernatremia |  | 
        |  | 
        
        | Term 
 
        | Mannitol - clinical applications? |  | Definition 
 
        | renal failure due to increased solute load (rhabdo, chemo), increased ICP, glaucoma |  | 
        |  | 
        
        | Term 
 
        | Mannitol - kinetics, tox? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Antagonist at V1a and V2 ADH receptors |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Reduces water reabsorption, increases plasma Na concentration |  | 
        |  | 
        
        | Term 
 
        | Conivaptan - clinical applications? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Conivaptan - kinetics, tox? |  | Definition 
 
        | IV only, infusion site reactions |  | 
        |  |